vimarsana.com
Home
Live Updates
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study o
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study o
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys AG
/ Key word: Miscellaneous
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023... | April 4, 2023
Related Keywords
Boston ,
Massachusetts ,
United States ,
Germany ,
Italy ,
Planegg ,
Bayern ,
Canada ,
Lugano ,
Italy General ,
American ,
German ,
Italian ,
Julia Neugebauer ,
Tim Demuth ,
Eamonn Nolan ,
Thomas Biegi ,
American Society Of Hematology ,
German Lymphoma Association ,
Drug Administration ,
Twitter ,
Constellation Pharmaceuticals Inc ,
Xencor Inc ,
Linkedin ,
Nasdaq ,
Us Oncology Network ,
Exchange Commission ,
Sys Completes Enrollment ,
Topline Results Expected ,
Chief Research ,
Development Officer ,
Myelofibrosis Symptom Assessment Form ,
American Society ,
Constellation Pharmaceuticals ,
Antibody Dependent Cell Mediated Cytotoxicity ,
Antibody Dependent Cellular Phagocytosis ,
Medication Guide ,
Prescribing Information ,
Patient Information ,
Important Safety ,
Diffuse Largeb Cell Lymphoma ,
Italian Lymphoma ,
Blinded Independent Review Committee ,
Morphosy Annual Report ,
Morphosys Ag Stock Exchange ,
News ,
Information ,
Press Release ,
Morphosys ,
Key ,
Ompletes ,
Enrollment ,
F ,
Hase ,
,
Study ,
Pelabresib ,
N ,
Myelofibrosis ,
Ith ,
Topline ,
Results ,
Xpected ,
Y ,
End ,
F Mor De0006632003 ,